A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer

Clinical trial NCT00058526 · COMPLETED

Trial details

NCT number: NCT00058526
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Neoplasms, Breast

Start date: 2003-03-20
Primary completion: 2006-09-06
Enrollment: 61

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.